医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SaferMe Contact Tracing App Selected by Selective Insurance, Helps Insurer Protect its Employees Returning to its Offices

2021年09月08日 PM09:00
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

Leading contact tracing app provider SaferMe announced today that award-winning property and casualty insurance carrier Selective Insurance Company of America, the lead insurer of Selective Insurance Group, Inc. (NASDAQ:SIGI), has renewed and expanded its commitment to SaferMe’s wearable contact tracing solution.

This follows Selective’s initial rollout of SaferMe at the beginning of its phased return to the office in February 2021.

“Our employees are the most important element of our success and helping ensure their safety is our priority. It’s vital that they feel comfortable and confident returning to work in our offices,” said Cyndi Bennett, Executive Vice President, Chief Human Resources Officer, Selective. “Contact tracing is an important part of our health and safety procedures and allows us to address COVID positive cases reported to us and minimize its spread.”

SaferMe provides purpose-built wearable cards that log interactions between employees using an anonymized and secure system to protect worker privacy and help enable businesses to stop large COVID clusters from developing in their workforces. This is done by instantly identifying workers who were in contact with other individuals who reported themselves as potentially or COVID positive.

“We want to help businesses and employees get back to their normal place of work as much as possible, and to do so safely,” said Clint Van Marrewijk, CEO of SaferMe. “Selective Insurance exemplifies what a thorough and thoughtful return to the office should look like. They’ve used our technology to help manage a safe return to all of its offices across the U.S. and provide employees peace of mind that COVID exposures can be effectively and timely tracked, reported, and mitigated.”

Selected by the New Zealand Government to provide business contact tracing via the MBIE Covid-19 response fund, SaferMe is now operating globally. Founded in Wellington, New Zealand, in 2015, SaferMe opened its US office in Austin, Texas, in early 2020.

Van Marrewijk added, “There are already more than 30 variants of the Sars-CoV-2 virus being monitored by global health authorities. To be proactive and prepared for the threat of new variants and seasonal spikes, organizations need to be able to prevent clusters of cases within their workforce.”

About SaferMe

SaferMe has emerged as a global leader in contact tracing solutions for business use. Selected by the New Zealand Government to provide business contact tracing via the MBIE Covid-19 response fund, SaferMe is now operating globally. Founded in Wellington, New Zealand, in 2015; SaferMe opened its US office in Austin, Texas, in early 2020, and has been experiencing strong growth – including among Fortune 500 clients and leading educational institutions. This demand is partly driven by being highlighted by the World Health Organization (WHO) for contact tracing capabilities and winning New Product of the Year in America’s OH&S Magazine Safety Awards.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005260/en/

CONTACT

For further information, please contact:

Rich Moore

Big Sprocket

T: (415) 608-7441

E: rich.moore@bigsprocketllc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™